Eli Lilly has won approval from Chinese regulators to sell its weight-loss treatment tirzepatide in the country, the company ...

Eli Lilly said in a social media post Friday its weight loss drug tirzepatide had received approval from Chinese regulators, ...

China’s National Medical Products Administration (NMPA) approved Eli Lilly And Co (NYSE:LLY) Tirzepatide for long-term weight ...

Eli Lilly (LLY) stock rises as Chinese drug regulator approves its weight loss therapy, tirzepatide, for long-term weight ...

Eli Lilly & Co.’s stock was on pace for its worst day in about three years Thursday as investors fretted about intensifying ...

Shares of weight-loss drug developers including Eli Lilly & Co., Novo Nordisk and Structure Therapeutics fell sharply early ...

Eli Lilly (LLY) and Novo Nordisk (NVO) under pressure as Roche (RHHBY) posts early-stage data for oral weight loss drug ...

Novo Nordisk and Eli Lilly shares slid Wednesday on promising early-stage trial data from Roche's latest obesity drug ...

Roche said that a Phase 1 clinical trial for CT-996, a once-daily oral GLP-1 receptor, showed positive top-line results.

Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on Eli Lilly with a price target of $885. Eli Lilly's ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart  has been straight up and to the right, up 553% and ...

Eli Lilly announces that its weight loss drug, tirzepatide, has been approved by Chinese regulators. This move intensifies ...